- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Mepolizumab Shows Promising Treatment of Severe Eosinophilic Asthma
In a recent multicenter study, Giulia Scioscia and peers found that in patients with severe eosinophilic asthma switching from mepolizumab to benralizumab can lead to improved treatment outcomes. The findings were published in Journal of Clinical Medicine.
Mepolizumab and benralizumab are monoclonal antibodies targeted against anti-IL-5 and anti-IL5R, respectively, and are commonly used in the treatment of severe eosinophilic asthma. These medications have been shown to reduce exacerbation rates and maintain oral corticosteroid requirements in patients with this condition.
The study included twenty-five patients with severe eosinophilic asthma who had been receiving mepolizumab for at least 12 months but showed a partial or total lack of clinical remission. The patients were switched to benralizumab, and their responses were assessed over a six-month period.
The results of the study revealed significant improvements in asthma control after the switch to benralizumab. At six months of treatment, patients exhibited significantly higher scores on the Asthma Control Test (ACT) compared to their scores while on mepolizumab. Furthermore, the number of daily short-acting beta-agonist (SABA) inhalations decreased significantly after six and twelve months of treatment with benralizumab compared to mepolizumab. Additionally, the intake of oral corticosteroids (OCS) was significantly reduced in patients receiving benralizumab.
Importantly, the study also identified a subgroup of patients with severe eosinophilic asthma and nasal polyposis who experienced marked improvements in asthma control, suppressed blood eosinophil levels, and a reduction in exacerbations following treatment with benralizumab.
These findings suggest that patients who initially showed a partial response to mepolizumab may benefit from switching to benralizumab. The study highlights the complexity of treating severe eosinophilic asthma and underscores the importance of personalized therapeutic choices based on individual patient factors. While this research provides valuable insights, further studies are warranted to validate these findings in larger patient populations and to explore the long-term effects of switching between these biologic medications.
Source:
Scioscia, G., Tondo, P., Nolasco, S., Pelaia, C., Carpagnano, G. E., Caiaffa, M. F., Valenti, G., Maglio, A., Papia, F., Triggiani, M., Vatrella, A., Foschino Barbaro, M. P., & Crimi, C. (2023). Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience. In Journal of Clinical Medicine (Vol. 12, Issue 13, p. 4362). MDPI AG. https://doi.org/10.3390/jcm12134362
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751